A multisociety Delphi consensus statement on new fatty liver disease nomenclatureMary E. Rinella, Zobair M. Younossi, Cynthia D. Guy et al.|Hepatology|2023Cited by 2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclatureMary E. Rinella, Zobair M. Younossi, Jeffrey V. Lazarus et al.|Journal of Hepatology|2023Cited by 2.7k
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)Frank Tacke, Dror Dicker, Paul Horn et al.|Journal of Hepatology|2024Cited by 1.6k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis WorseningVlad Ratziu, Velimir A. Luketic, Juan F. Gallegos‐Orozco et al.|Gastroenterology|2016Cited by 1k
A multisociety Delphi consensus statement on new fatty liver disease nomenclatureMary E. Rinella, Zobair M. Younossi, Jeffrey V. Lazarus et al.|Annals of Hepatology|2023Cited by 789